多发性骨髓瘤细胞分子遗传学为基础的预后分层与个体化治疗进展

Molecular genetics-based prognosis stratification and individualized treatment of multiple myeloma cells

多发性骨髓瘤(MM)是骨髓中浆细胞克隆性增殖的恶性疾病,其生物学异质特性较高,因患者个体之间具有明显差别,所以在治疗时,患者生存期存在明显差异,可为数月,也可为十多年。采用合理预后分层评估方法,对于多发性骨髓瘤治疗具有重要意义。细胞分子遗传学异常对多发性骨髓瘤预后具有重要影响,将分子遗传学作为基础,建立有效预后分层方法,可使得患者得到更为针对性的个体化治疗。

Multiple myeloma(MM)is a malignant disease of clonal proliferation of plasma cells in the bone marrow.Its biological heterogeneity is high.Because there are obvious differences between individual patients,the survival time of patients is obvious during treatment.The difference can be months or more than ten years.Using a reasonable prognostic stratified assessment method is of great significance for the treatment of multiple myeloma.Cellular molecular genetic abnormalities have an important impact on the prognosis of multiple myeloma.Using molecular genetics as the basis and establishing an effective prognostic stratification method can enable patients to receive more targeted individualized treatment.